Premium
Functional polymorphism of matrix metalloproteinase‐9 (MMP‐9) gene and response to lithium prophylaxis in bipolar patients
Author(s) -
Rybakowski Janusz K.,
Skibinska Maria,
Suwalska Aleksandra,
LeszczynskaRodziewicz Anna,
Kaczmarek Leszek,
Hauser Joanna
Publication year - 2011
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1182
Subject(s) - bipolar disorder , genotype , medicine , lithium (medication) , matrix metalloproteinase 9 , polymorphism (computer science) , pharmacogenetics , mood disorders , gastroenterology , oncology , psychiatry , matrix metalloproteinase , gene , genetics , biology , anxiety
Objective Matrix metalloproteinase 9 (MMP‐9) has been implicated in a number of pathological conditions including cancer and heart diseases, and recently also in such neuropsychiatric disorders as schizophrenia and bipolar illness. Therefore, we investigated a possible association between functional polymorphisms of the MMP‐9 gene and the response to lithium, the main mood‐stabilizing drug in bipolar illness. Methods One hundred and nine bipolar patients treated with lithium for at least 5 years were analyzed. The lithium response was assessed as—excellent: no affective episodes during lithium treatment; partial: 50% or more reduction in the episode index; no response: less than 50% reduction, no change or worsening in the episode index. The ‐1562C/T MMP‐9 gene polymorphism ( rs3918242 ) was assessed by PCR‐RFLP method. Results Genotype distributions were not in Hardy–Weinberg equilibrium. No association was found between polymorphism studied and the quality of response to prophylactic lithium administration. Conclusion The functional polymorphism of the MMP‐9 gene , analyzed in this study, may not be associated with the treatment response to lithium in bipolar patients. Copyright © 2011 John Wiley & Sons, Ltd.